Fate Therapeutics (FATE) Tops Q3 EPS by 10c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.46), $0.10 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $1.94 million versus the consensus estimate of $1.59 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Epsilon Energy Ltd. (EPSN) Reports Q2 EPS of $0.23
• RenovoRx, Inc. (RNXT) Tops Q2 EPS by 2c